ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ODD ODDITY Tech Ltd.

Not Yet Opened 05-21 16:00:00 EDT

12.39

-0.12

-0.96%

盘后12.79

+0.40+3.23%

18:39 EDT

High12.57	Low11.81	Vol1.55M
Open12.49	D1 Closing12.51	Amplitude6.08%
Mkt Cap701.98M	Tradable Cap485.27M	Total Shares56.66M
T/O18.91M	T/O Rate3.95%	Tradable Shares39.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ODD","market":"US","secType":"STK","nameCN":"ODDITY Tech Ltd.","latestPrice":12.39,"timestamp":1779393600000,"preClose":12.51,"halted":0,"volume":1546312,"hourTrading":{"tag":"盘后","latestPrice":12.79,"preClose":12.39,"latestTime":"18:39 EDT","volume":24780,"amount":309074.31,"timestamp":1779403165815,"change":0.4,"changeRate":0.032284,"amplitude":0.032284},"delay":0,"changeRate":-0.009592326139088666,"floatShares":39166500,"shares":56656685,"eps":1.791771,"marketStatus":"Not Yet Opened","change":-0.12,"latestTime":"05-21 16:00:00 EDT","open":12.49,"high":12.57,"low":11.81,"amount":18910401.481384,"amplitude":0.060751,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.791771,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779436800000},"marketStatusCode":0,"adr":0,"listingDate":1689739200000,"exchange":"NASDAQ","adjPreClose":12.51,"preHourTrading":{"tag":"盘前","latestPrice":12.51,"preClose":12.51,"latestTime":"09:25 EDT","volume":505,"amount":6462.440055,"timestamp":1779369930031,"change":0,"changeRate":0,"amplitude":0.028777},"postHourTrading":{"tag":"盘后","latestPrice":12.79,"preClose":12.39,"latestTime":"18:39 EDT","volume":24780,"amount":309074.31,"timestamp":1779403165815,"change":0.4,"changeRate":0.032284,"amplitude":0.032284},"volumeRatio":1.115499,"impliedVol":0.7239,"impliedVolPercentile":0.568},"requestUrl":"/m/hq/s/ODD/wiki","defaultTab":"wiki","newsList":[{"id":"2637353557","title":"KeyBanc card data shows ‘significant improvement’ for Oddity","url":"https://stock-news.laohu8.com/highlight/detail?id=2637353557","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637353557?lang=en_us&edition=fundamental","pubTime":"2026-05-22 00:30","pubTimestamp":1779381013,"startTime":"0","endTime":"0","summary":"KeyBanc says the firm’s credit card data shows “significant improvement” for Oddity (ODD) in May following weakness seen in April. Consolidated spe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/keybanc-card-data-shows-significant-improvement-for-oddity-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/keybanc-card-data-shows-significant-improvement-for-oddity-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD","IE0009354923.USD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637382217","title":"Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2637382217","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637382217?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:30","pubTimestamp":1779359400,"startTime":"0","endTime":"0","summary":"LOS ANGELES, May  21, 2026  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299136/0/en/Immix-Biopharma-Announces-Pricing-of-150-Million-Underwritten-Offering-of-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053666078.USD","LU0314104364.USD","LU0528227936.USD","LU1162221912.USD","LU1732800096.USD","LU2347655156.SGD","BK4183","LU1732799900.SGD","LU1244550221.USD","BK4581","LU1074936037.SGD","LU1244550494.USD","LU2089284900.SGD","IE00BKVL7J92.USD","LU0106831901.USD","LU0158827781.USD","LU0557290698.USD","LU0795875086.SGD","LU2487616109.SGD","BK4127","LU0106261372.USD","BK4516","LU1668664300.SGD","LU0912757837.SGD","LU2089283258.USD","ODD","LU0234570918.USD","LU0390134368.USD","BK4588","LU1244550577.SGD","LU0795875169.SGD","LU1791710400.SGD","LU0006306889.USD","LU0882574139.USD","LU1989772923.USD","LU0098860793.USD","LU1720051017.SGD","LU1363072403.SGD","BK4534","IE0009354923.USD","LU0320765646.SGD","BK4585","LU2028103732.USD","LU0225283273.USD","IE00BZ1G4Q59.USD","LU1720051108.HKD","LU1791710582.SGD","LU2111349929.HKD","LU2271345857.HKD","LU1988902786.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637843043","title":"Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2637843043","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637843043?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:00","pubTimestamp":1779357600,"startTime":"0","endTime":"0","summary":"– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-dosing – – N","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299108/0/en/Immix-Biopharma-Announces-95-Complete-Response-Rate-in-Interim-Update-From-relapsed-refractory-AL-Amyloidosis-Clinical-Trial-NEXICART-2.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","ODD","LU1169590202.USD","BK4572","IE0034390439.USD","BK4230","BK4161","BK4022","CR","AL","LU1169589451.USD","IE00B19Z6F94.USD","IE0009354923.USD","CAR","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636260510","title":"Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2636260510","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636260510?lang=en_us&edition=fundamental","pubTime":"2026-05-18 17:10","pubTimestamp":1779095400,"startTime":"0","endTime":"0","summary":"Current treatments are limited by suboptimal disease control and treatment-related complications3,4. Asedebart  is a novel, investigational anti-ACTH monoclonal antibody targeting underlying disease pathology. Proof-of-concept trials are currently ongoing to evaluate efficacy and safety of asedebart in CD and CAH. VALBY, Denmark, May 18, 2026 /PRNewswire/ --Lundbeck today announced that orphan drug designation  has been granted in Japan by the Ministry of Health, Labour and Welfare  for asedebart  for the treatment of patients with congenital adrenal hyperplasia  and Cushing's disease .Asedebart, a novel monoclonal antibody targeting ACTH is advancing in clinical development as a potential first-in-class treatment for conditions characterized by excess ACTH. By targeting an underlying disease mechanism, asedebart aims to offer a new treatment approach to managing CAH. Asedebart, formerly designated Lu AG13909, has recently been assigned an International Nonproprietary Name  and has rec","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/lundbeck-receives-orphan-drug-designation-in-japan-for-asedebart-for-the-treatment-of-patients-with-congenital-adrenal-hyperplasia-and-cushings-disease-302774519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","LU1267930227.SGD","LU1880398554.USD","BK4175","LU0162691827.USD","LU0052756011.USD","LU1267930490.SGD","LU1983299246.USD","LU0310800965.SGD","LU0211328371.USD","LU1571399168.USD","LU0889566641.SGD","ODD","BK4183","LU1880398471.USD","LU0072461881.USD","BK4585","CAH","BK4116","LU0006061336.USD","LU0128525689.USD","BK4588","SG9999001440.SGD","CD","LU0154236417.USD","LU0310799852.SGD","INN","BK4023","LU1267930813.SGD","LU0792757196.USD","LU0211327993.USD","BK4181","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635058439","title":"Press Release: TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635058439","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635058439?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:00","pubTimestamp":1778878800,"startTime":"0","endTime":"0","summary":"TAMPA, Fla., May 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's first quarter ended March 31, 2026, and provided a corporate update.\"I am very pleased with the progress we have made this past quarter as we continue to execute upon our corporate and development strategy. Importantly, we recently established a $50 million non-equity-based source of operating capital in the form of credit facility with our largest stockholder on attractive terms for the company allowing us to fund operations beyond anticipated top-line data in our lead IFx-2.0 program,\" said Dr. James Bianco, President and CEO of TuHURA Biosciences. \"With the financing optionality provided by the credit facility, we now look forward to several anticipated key upcoming milestones, including: meeting with the FDA to discuss our IND and development plan for o","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4022","R","IE0009354923.USD","ODD","BK4139","BK4183","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635308732","title":"Oddity Tech schedules first-quarter results release, earnings call","url":"https://stock-news.laohu8.com/highlight/detail?id=2635308732","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635308732?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:02","pubTimestamp":1778850159,"startTime":"0","endTime":"0","summary":"Oddity Tech schedules release of first-quarter 2026 financial results before U.S. market open on June 2, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL4X82dQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","LU0314104364.USD","SG9999014039.USD","NDAQ","BK4183","ODD","LU2210149790.SGD","BK4588","SG9999014013.SGD","IE00BN0W2W23.USD","LU2095319765.USD","IE0009354923.USD","IE00B3QW5Z07.USD","BK4112","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635208722","title":"ODDITY to Announce First Quarter 2026 Financial Results on June 2, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635208722","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635208722?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:00","pubTimestamp":1778850000,"startTime":"0","endTime":"0","summary":"NEW YORK, May  15, 2026  (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (“ODDITY”) (NASDAQ: ODD), today announced that it will release its first quarter 2026 financial results before the market open on Tuesday,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/15/3295899/0/en/ODDITY-to-Announce-First-Quarter-2026-Financial-Results-on-June-2-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","IE0009354923.USD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635710850","title":"Press Release: Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2635710850","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635710850?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:45","pubTimestamp":1778762700,"startTime":"0","endTime":"0","summary":"Secured strategic financing vehicle for up to $40 million. Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn. SOUTH SAN FRANCISCO, Calif., May 14, 2026  -- Senti Biosciences Holdings, Inc.  , a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.In addition, Senti announced that it identified a specific Donor X attribute that correlates with efficacy of SENTI-202, with 50%  of the patients achieving a composite CR  when they received any SENTI-202 doses manufactured from Donor X-characteristic derived NK cells in Cycle 1. The Donor X attribute is found in 50% of","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1363072403.SGD","ODD","LU2237443549.SGD","IE00BFXG1179.USD","CMC","IE0009354923.USD","LU0170899867.USD","LABU","LU2746668461.USD","BK4588","IE00B1BXHZ80.USD","BK4183","IE00BKVL7J92.USD","LU2237443622.USD","LU2237443895.HKD","LU2237443978.SGD","LU2237443465.HKD","BK4539","IE00BHPRN162.USD","LU2746668974.SGD","LU0149725797.USD","BK4006","LU0267386448.USD","IE00BZ1G4Q59.USD","LU0971096721.USD","LU0882574139.USD","SNTI","BK4585","LU2237443382.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717059","title":"Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717059","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717059?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:40","pubTimestamp":1778762400,"startTime":"0","endTime":"0","summary":"Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294958/0/en/Senti-Biosciences-Holdings-Announces-Positive-FDA-RMAT-Meeting-on-Registrational-Clinical-and-CMC-Strategy-for-SENTI-202-in-Relapsed-Refractory-AML-Along-with-Important-Efficacy-an.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443895.HKD","LU2237443382.USD","LU2237443549.SGD","LU2413666426.HKD","BK4585","BK4121","LABU","LD","LU2413666699.HKD","BK4567","SOCL","LU0170899867.USD","IE0009354923.USD","IE00BFXG0V08.USD","BK4183","IE00B1BXHZ80.USD","IE00BYQQ9H92.USD","LU0971096721.USD","IE00B5TLWC47.USD","IE00BZ1G4Q59.USD","BK4006","LU1721428933.USD","BK4588","LU2746668974.SGD","LU0347712357.USD","CMC","BK4548","LU0149725797.USD","LU2211817866.USD","MTD","LU0882574139.USD","LU2237443622.USD","LU2746668461.USD","IE00BKVL7J92.USD","LU2237443465.HKD","IE00BHPRN162.USD","LU2237443978.SGD","BK4533","LU1363072403.SGD","LU1093756325.SGD","LU1093756168.USD","IE00BFXG1179.USD","ODD","LU0267386448.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242533","title":"U.S. Earnings Preview: After Market Close May 12","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242533","media":"Dow Jones","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242533?lang=en_us&edition=fundamental","pubTime":"2026-05-13 03:31","pubTimestamp":1778614260,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.The following companies are among those expected to report their latest financial results after the market closes.Resideo Technologies Inc.'s first-quarter EPS is forecast at 60 cents, compared with a loss of 2 cents in the prior-year period. Adjusted EPS is forecast at 61 cents.Astronics Corp.'s first-quarter EPS is forecast at 32 cents. Adjusted EPS is forecast at 56 cents.Arteris Inc.'s first-quarter EPS is forecast at a loss of 19 cents, compared with a loss of 20 cents in the prior-year period. Adjusted EPS is forecast at a loss of 7 cents.PennantPark Floating Rate Capital Ltd.'s second-quarter EPS is forecast at 28 cents, compared with 19 cents in the prior-year period. Adjusted EPS is forecast at 27 cents.Kura Oncology Inc.'s first-quarter EPS is forecast at a loss of 83 cents, compared with a loss of 66 cents in the prior-year period.Gladstone Investment Corp.'s fourth-quarter EPS is ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4187","IE00B19Z4B17.USD","IE0031619046.USD","ATRO","IE00B7SZL793.SGD","BK4097","IE0009354923.USD","PFLT","BK4086","GAIN","REZI","AIP","BK4139","IE00B66KJ199.SGD","ODD","BK4505","KURA","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634219035","title":"PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2634219035","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634219035?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587200,"startTime":"0","endTime":"0","summary":"Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew England Journal of Medicine published first-in-human reza","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3292786/0/en/PMV-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","ODD","BK4139","BK4183","IE0009354923.USD","PMVP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634138492","title":"Press Release: Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634138492","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634138492?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:05","pubTimestamp":1778583900,"startTime":"0","endTime":"0","summary":"-- U.S. Food and Drug Administration  review of oxylanthanum carbonate.  New Drug Application  resubmission remains on track, with a. Prescription Drug User Fee Act  target action date of June 29,\"As we approach the June 29th PDUFA target action date, we remain optimistic about the potential approval of OLC and focused on preparations for the subsequent launch of OLC,\" said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. \"Our ongoing dialogue with the FDA during the review cycle has been constructive and timely. Uncontrolled hyperphosphatemia remains a significant health concern, affecting nearly 75% of U.S. patients with chronic kidney disease who are undergoing dialysis. OLC has the potential to improve adherence and phosphorus control with reduced pill burden, compared with currently available phosphate binders.\". a bioequivalence study in healthy volunteers, and a tolerability study in. patients with CKD on dialysis), multiple preclinical studies, and. continues to stren","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMC","BK4183","LU2237443622.USD","IE00B1BXHZ80.USD","LU2237443978.SGD","LU0971096721.USD","IE00BKVL7J92.USD","LU2746668461.USD","LU2237443895.HKD","BK4539","LU0149725797.USD","LU0882574139.USD","BK4139","IE00BFXG1179.USD","ODD","03160","LU0170899867.USD","UNCY","LU1363072403.SGD","IE0009354923.USD","IE00BZ1G4Q59.USD","BK4555","BK4588","TM","LABU","BK4585","LU0267386448.USD","BK4099","IE00BHPRN162.USD","LU2746668974.SGD","BK4604","LU2237443465.HKD","BK4006","LU2237443549.SGD","LU2237443382.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633140669","title":"Oddity Tech faces shareholder class action over alleged digital ad cost misstatements","url":"https://stock-news.laohu8.com/highlight/detail?id=2633140669","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633140669?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:04","pubTimestamp":1778159081,"startTime":"0","endTime":"0","summary":"Class action filed for shareholders who bought Oddity Tech securities between Feb. 26, 2025 and Feb. 24, 2026, alleging misstatements tied to customer acquisition costs and digital ad performance.Shares fell USD 14.28, or 49.21%, to USD 14.74 on Feb. 25, 2026 following disclosure of a severe disruption in digital advertising operations.Complaint alleges an algorithm change at its largest advertising partner pushed ads into lower-quality auctions, driving higher costs and weaker performance, while guidance was raised through three consecutive quarters.SG&A, including advertising, rose to USD 158.18 million in Q1 2025 from USD 117.13 million in Q1 2024, cited as evidence of escalating acquisition costs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL3JpRTv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","IE0009354923.USD","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633914226","title":"Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633914226","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633914226?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:30","pubTimestamp":1778157000,"startTime":"0","endTime":"0","summary":"– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome  – Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW Confi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290007/0/en/Quoin-Pharmaceuticals-Provides-Corporate-Update-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","IE0009354923.USD","IND","BK4588","QNRX","BK4585","ODD","BK4139","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633591711","title":"Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2633591711","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633591711?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:02","pubTimestamp":1778097720,"startTime":"0","endTime":"0","summary":"Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3289308/0/en/Revolution-Medicines-Reports-First-Quarter-2026-Financial-Results-and-Update-on-Corporate-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4512","BK4213","CRC","LU1861214812.USD","LU2360107325.USD","LU0348723411.USD","IE00BD6J9T35.USD","BK4141","IE0009354923.USD","LU0124384867.USD","BK4588","IE00BFMHRM44.USD","BK4195","LU1720051017.SGD","LU0724618433.USD","RVMD","LU2357305700.SGD","BK4211","LU1861220033.SGD","LU1861219969.SGD","EMA","LU2065732104.USD","PRGS","BK4605","BK4081","LU0456854461.SGD","BK4097","LU1854103824.USD","BK4139","BMS","LU1861215975.USD","LU0266512127.USD","ODD","ON","BK4183","IE00BZ199S13.USD","LU1978683503.SGD","LU1548497426.USD","LU1854104046.USD","BK4585","LU2298322129.HKD","PFS","LU1720051108.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632767570","title":"Oddity Tech (ODD) Is Down 8.5% After Class Action Over Ad Cost Disclosures - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2632767570","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632767570?lang=en_us&edition=fundamental","pubTime":"2026-05-02 21:40","pubTimestamp":1777729231,"startTime":"0","endTime":"0","summary":"The Gross Law Firm recently announced a class action lawsuit on behalf of Oddity Tech shareholders, alleging the company made materially false and misleading statements about digital advertising costs after an algorithm change by its largest advertising partner increased customer acquisition costs and hurt its business outlook.\nThis legal challenge raises fresh questions about how dependent Oddity’s business model is on a single digital ad ecosystem and the transparency of its cost...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/oddity-tech-odd-is-down-85-after-class-action-over-ad-cost-d","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/oddity-tech-odd-is-down-85-after-class-action-over-ad-cost-d","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4587","AGIX","BK4551","BK4585","BK4023","AIPO","AIYY","BK4528","ARTY","BK4543","BK4588","ODD","BK4183","CHAT","AI","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632661534","title":"A Look At Oddity Tech (ODD) Valuation After Class Action Lawsuit On Advertising Disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2632661534","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632661534?lang=en_us&edition=fundamental","pubTime":"2026-05-01 17:41","pubTimestamp":1777628490,"startTime":"0","endTime":"0","summary":"Class action lawsuit puts Oddity Tech (NasdaqGM:ODD) disclosures in focus\nA recent notice from The Gross Law Firm about a class action lawsuit against Oddity Tech (NasdaqGM:ODD) alleges misleading statements around digital advertising costs after an algorithm change by its largest advertising partner.\nSee our latest analysis for Oddity Tech.\nThe class action headlines arrive after a sharp reset in sentiment, with a 1 year total shareholder return of about 78% decline and a 90 day share price...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/a-look-at-oddity-tech-odd-valuation-after-class-action-lawsu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/a-look-at-oddity-tech-odd-valuation-after-class-action-lawsu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CHAT","BK4588","AIYY","AGIX","BK4023","BK4585","BK4183","BK4587","BK4528","BK4551","BK4543","AIPO","ARTY","AI","ODD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631637932","title":"Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631637932","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631637932?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:30","pubTimestamp":1777552200,"startTime":"0","endTime":"0","summary":"FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to stand","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284867/0/en/Cadrenal-Therapeutics-Announces-End-of-Phase-2-Meeting-with-the-FDA-and-Pivotal-Phase-3-Registration-Path-for-CAD-1005-in-Heparin-Induced-Thrombocytopenia-HIT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LABU","BK4585","LENZ","BK4139","HIT","BK4588","ODD","BK4173","IE0009354923.USD","BK4539","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631580707","title":"Oddity price target lowered to $14 from $18 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2631580707","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631580707?lang=en_us&edition=fundamental","pubTime":"2026-04-29 03:10","pubTimestamp":1777403419,"startTime":"0","endTime":"0","summary":"Jefferies lowered the firm’s price target on Oddity (ODD) to $14 from $18 and keeps a Hold rating on the shares. The firm is reducing estimates fur...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oddity-price-target-lowered-to-14-from-18-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oddity-price-target-lowered-to-14-from-18-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD","BK4183","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630589138","title":"Creating a Sustainable Impact: Fosun International Releases 2025 ESG Report and Climate Information Disclosures Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2630589138","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630589138?lang=en_us&edition=fundamental","pubTime":"2026-04-28 23:04","pubTimestamp":1777388640,"startTime":"0","endTime":"0","summary":"HONG KONG, April 28, 2026 /PRNewswire/ --Fosun International Limited , together with its subsidiaries , released the Environmental, Social and Governance  Report 2025 . Facing the increasingly severe challenges of global climate change, Fosun released its fourth Climate Information Disclosures Report with reference to Part D  of Appendix C2 \"Environmental, Social and Governance Reporting Code\" of the Main Board Listing Rules of the Hong Kong Stock Exchange, the framework of the Task Force on Climate-Related Financial Disclosures  recommendations and the International Financial Reporting Standards S2 Climate-related Disclosures Requirements .As an industry group rooted in China with a global presence, Fosun always places sustainability at the core of its strategy, responding to the expectations of the times and society through concrete actions. Fosun's sustainable development strategy, \"Create IMPACT\", centers on six long-term strategic directions, which stand for I: Innovation-driven, ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/creating-a-sustainable-impact-fosun-international-releases-2025-esg-report-and-climate-information-disclosures-report-302755896.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFC.AU","BK4211","BK4134","BFC","BK7509","BK4201","EC","III","IE0009354923.USD","ODD","BK4183","ESG","BK7505","ICCC","BK7141","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://oddity.com","stockEarnings":[{"period":"1week","weight":-0.012},{"period":"1month","weight":-0.1996},{"period":"3month","weight":-0.6128},{"period":"6month","weight":-0.6714},{"period":"1year","weight":-0.8088},{"period":"ytd","weight":-0.6916}],"compareEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":0.0549},{"period":"3month","weight":0.0773},{"period":"6month","weight":0.127},{"period":"1year","weight":0.2743},{"period":"ytd","weight":0.0892}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oddity Tech Ltd. operates as a consumer tech company that builds and scales digital-first brands to disrupt beauty and wellness industries. The company serves consumers worldwide through its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. It owns IL MAKIAGE and SpoiledChild brands. The company was incorporated in 2013 and is headquartered in Tel Aviv, Israel with additional office in New York, New York.","exchange":"NASDAQ","name":"ODDITY Tech Ltd.","nameEN":"ODDITY Tech Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ODDITY Tech Ltd.(ODD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ODDITY Tech Ltd.,ODD,ODDITY Tech Ltd.股票,ODDITY Tech Ltd.股票老虎,ODDITY Tech Ltd.股票老虎国际,ODDITY Tech Ltd.行情,ODDITY Tech Ltd.股票行情,ODDITY Tech Ltd.股价,ODDITY Tech Ltd.股市,ODDITY Tech Ltd.股票价格,ODDITY Tech Ltd.股票交易,ODDITY Tech Ltd.股票购买,ODDITY Tech Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ODDITY Tech Ltd.(ODD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}